Vitae Pharmaceuticals (VTAE) Reports In-Line Q4 Loss of 40c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq rallies as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts VTAE Hot Sheet
Join SI Premium – FREE
Vitae Pharmaceuticals (NASDAQ: VTAE) reported Q4 EPS of ($0.40), in-line with the analyst estimate of ($0.40). Revenue for the quarter came in at $161.7 thousand versus the consensus estimate of $100 thousand.
For earnings history and earnings-related data on Vitae Pharmaceuticals (VTAE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Expedia (EXPE) PT Raised to $204 at Stifel
- Expeditors Int'l (EXPD) Tops Q3 EPS by 45c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
